Photo by rhweht from unsplash
In the EXPLORER‐HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO2)… Click to show full abstract
In the EXPLORER‐HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO2) and New York Heart Association (NYHA) class, were greater in patients not receiving background beta‐blockers than in those receiving beta‐blockers. We sought to determine if the effect of background treatment was consistent across other clinically meaningful parameters.
Journal Title: European Journal of Heart Failure
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!